No Data
CK Life Sciences Swings to Loss in 2024; Shares Fall 3%
CKLIFE SCIENCES (00775.HK) reported a loss of 0.127 billion Hong Kong dollars for the fiscal year 2024.
Gelonghui reported on March 18 that CKLIFE SCIENCES (00775.HK) announced that in the fiscal year 2024, the company's revenue reached 5.523 billion HKD, compared to 5.323 billion HKD in the same period last year; annual loss of 0.127 billion HKD, compared to a profit of 17.25 million HKD in the same period last year; loss per share of 1.32 cents.
Express News | CK Life Sciences Intl (Holdings) FY Net Income HKD -126.6 Million
CKLIFE SCIENCES: ANNUAL RESULTS FOR 2024
CKLIFE SCIENCES (00775.HK) has entered into a debt exchange agreement.
On March 12, 2023, Gelonghui reported that CKLIFE SCIENCES (00775.HK) announced that, according to the loan agreement, $16.5 million from the 2024 loan was withdrawn by the buyer Dogwood Therapeutics, Inc. on October 7, 2024, and $3 million from the 2025 loan was withdrawn by the buyer on February 18, 2025, with accrued interest of $426,891 as of March 12, 2025. On March 12, 2025, the lender (a wholly-owned subsidiary of the company) and the buyer entered into a debt exchange agreement, under which the lender and
Investors in CK Life Sciences Int'l. (Holdings) (HKG:775) From Five Years Ago Are Still Down 34%, Even After 10.0% Gain This Past Week
Investors Don't See Light At End Of CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Tunnel And Push Stock Down 26%
